Loading clinical trials...
Loading clinical trials...
A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Conditions
Interventions
rIX-FP
Locations
42
United States
University of Colorado
Aurora, Colorado, United States
Indiana Hemophilia & Thrombosis Center Inc.
Indianapolis, Indiana, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
Royal Children's Hospital
Parkville, Victoria, Australia
The Children's Hospital Westmead
Westmead, Victoria, Australia
Start Date
February 6, 2014
Primary Completion Date
June 2, 2021
Completion Date
June 2, 2021
Last Updated
July 14, 2022
NCT06379789
NCT06008938
NCT04645199
NCT07080905
NCT06700096
NCT06312475
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions